SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) ...

PE Hub has rounded up six deals going back to early January involving companies in the oncology segment, starting with the ...

The latter is split into two types: deterministic risks,1 determined by the threshold dose, as represented by skin injury and stochastic risks, determined by a linear no-threshold model, such as the ...

SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative ...

SYDNEY, June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm” or the "Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology ...

Gastrointestinal stromal tumors are among the first solid tumors for which cancer-(cell-)specific therapy became available. What is its pathogenesis, therapy strategies and drug resistance mechanisms?

JNJ-1900 (NBTXR3) is a novel intratumoral radioenhancer, activated by radiation therapy, which is being investigated in phase 1 clinical research for patients with lung cancer, according to Dr. Jared ...

Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors ...

251776 Introduction: Recently, there are some studies showing the value of 68Ga-DOTA-FAPI-04 PET in the detection of metastatic gastrointestinal stromal tumor (GIST). However, only a few cases have ...